Finance

Lists
RDY:NYSE
डक्टर रेड्डीज
US$ १३.०७
+१.३२%
(+०.१७) 1D
US$ १३.०७
०.००% (०.००)
After hours
Closed: अक्टोबर १६, १६:००:०७ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
US$ १३.००
High
US$ १३.०७
Low
US$ १२.९४
Mkt. cap
१०.८१ अरब
Avg. vol.
३१.८८ लाख
Volume
२७.९४ लाख
Dividend
०.६४%
Quarterly dividend
US$ ०.०२
Ex-dividend date
२०२६ जुलाई १०
P/E ratio
३१.३४
52-wk high
US$ १५.६७
52-wk low
US$ ११.३६
EPS
US$ ०.४२
Beta
०.३०
Shares outstanding
८३.४६ करोड
No. of employees
२८ हजार
Open
US$ १३.००
High
US$ १३.०७
Low
US$ १२.९४
Mkt. cap
१०.८१ अरब
Avg. vol.
३१.८८ लाख
Volume
२७.९४ लाख
Dividend
०.६४%
Quarterly dividend
US$ ०.०२
Ex-dividend date
२०२६ जुलाई १०
P/E ratio
३१.३४
52-wk high
US$ १५.६७
52-wk low
US$ ११.३६
EPS
US$ ०.४२
Beta
०.३०
Shares outstanding
८३.४६ करोड
No. of employees
२८ हजार
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About डक्टर रेड्डीज
CEOErez Israeli
Employees२७.५ हजार
Founded१९८४
Headquartersहैदराबाद, आन्ध्र प्रदेश, भारत
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to RDY in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RDY in the last 3 months.
Highest
Current US$ १३.०७
US$ १४.८० (+१३.२४%)
Average
US$ १४.८० (+१३.२४%)
Lowest
US$ १४.८० (+१३.२४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tausif Shaikh
Exane BNP Paribas
Buy
Upgraded
US$ १४.८०
+१३.२%
10/12/2026
Neha Manpuria
Bank of America Securities
Buy
Maintained
-
-
10/01/2026
Unknown Analyst
Citi
Sell
Maintained
-
-
04/23/2026
Next call ५ दिनमा
अक्टोबर २३, शुक्र, १६:००
Fiscal period
Q2 2027
- / ₹ ८.९५
Revenue / Est. (INR)
- / ८५.९४ अरब
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
८८.०५ अरब
८७.२७ अरब
७५.१६ अरब
८०.७० अरब
Cost of goods sold
३९.९१ अरब
४०.४६ अरब
४१.४७ अरब
४३.१६ अरब
Cost of revenue
३९.९१ अरब
४०.४६ अरब
४१.४७ अरब
४३.१६ अरब
Research and development expenses
६.२० अरब
६.१५ अरब
५.४६ अरब
५.७७ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२६.४४ अरब
२६.९२ अरब
२७.७६ अरब
२८.८२ अरब
Operating expense
३१.९० अरब
३२.४८ अरब
३२.५३ अरब
३४.११ अरब
Total operating expenses
७१.८१ अरब
७२.९४ अरब
७४.०० अरब
७७.२७ अरब
Operating income
१६.२४ अरब
१४.३३ अरब
१.१६ अरब
३.४३ अरब
Other non operating income
१.२८ अरब
५७.०० करोड
५१.२० करोड
-
EBT including unusual items
१८.३५ अरब
१५.४३ अरब
१.९९ अरब
५.५३ अरब
EBT excluding unusual items
१७.८१ अरब
१५.५२ अरब
१.८२ अरब
४.०९ अरब
Income tax expense
४.०८ अरब
३.५३ अरब
-२१.४० करोड
१.१८ अरब
Effective tax rate
२२.२४%
२२.९०%
-१०.७५%
२१.३२%
Other operating expenses
-७४.०० करोड
-५९.१० करोड
-६९.३० करोड
-४७.७० करोड
Net income
१४.३७ अरब
१२.१० अरब
२.२० अरब
४.४४ अरब
Net profit margin
१६.३२%
१३.८६%
२.९३%
५.५०%
Earnings per share
१७.८७
१४.७७
५.७४
५.३३
Interest and investment income
९१.२० करोड
७९.६० करोड
८९.०० करोड
९९.९० करोड
Interest expense
-९०.७० करोड
-९४.४० करोड
-१.०६ अरब
-१.२६ अरब
Net interest expenses
५०.०० लाख
-१४.८० करोड
-१६.७० करोड
-२५.६० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
२१.२९ अरब
१९.५४ अरब
५.०३ अरब
८.८० अरब
Gain or loss from assets sale
-३०.८० करोड
-१७.९० करोड
-२.१० अरब
-३६.८० करोड
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू